These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28185213)

  • 1. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a)-apheresis in the light of new drug developments.
    Vogt A
    Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
    Heigl F; Pflederer T; Klingel R; Hettich R; Lotz N; Reeg H; Schettler VJJ; Roeseler E; Grützmacher P; Hohenstein B; Julius U
    Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
    Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
    Mickiewicz A; Marlega J; Kuchta A; Bachorski W; Cwiklinska A; Raczak G; Gruchala M; Fijalkowski M
    J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
    Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
    Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R; Heibges A; Fassbender C;
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
    Grützmacher P; Öhm B; Szymczak S; Dorbath C; Brzoska M; Kleinert C
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia.
    Pokrovsky SN; Afanasieva OI; Ezhov MV
    Curr Atheroscler Rep; 2020 Sep; 22(11):68. PubMed ID: 32945973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy.
    Sbrana F; Bigazzi F; Corciulo C; Dal Pino B
    Eur J Prev Cardiol; 2024 Jun; 31(8):e62-e64. PubMed ID: 38470832
    [No Abstract]   [Full Text] [Related]  

  • 19. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Hohenstein B; Tselmin S; Bornstein SR; Julius U
    Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.